WEST:NASDAQWestrock Coffee Company Analysis
Data as of 2026-08-01 - not real-time
$8.12
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Westrock Coffee (WEST) is trading around $8.12, just below the calculated resistance of $8.45 and slightly above both its 20‑day ($7.58) and 50‑day ($8.10) simple moving averages, suggesting limited upside in the immediate term. The RSI sits near 55, indicating a neutral momentum environment, while the MACD histogram is positive and the signal line is bullish, providing a modest technical lift. However, volume is on a decreasing trend and 30‑day volatility is elevated at roughly 68%, which adds short‑term uncertainty. On the fundamentals side, the company posted a striking 44% revenue growth year‑over‑year, yet margins remain thin (gross margin ~13%, operating margin ~2.6%) and earnings are negative, reflected in a trailing EPS of –$0.74 and a forward PE of 45. The balance sheet shows a very high debt‑to‑equity ratio (≈270) and a negative book value per share, while the DCF‑derived fair value of about $2.96 is far below the current price, implying the stock is materially overvalued. Analyst consensus is a strong‑buy with a median target near $8.75, but the market sentiment index is in “Extreme Greed” territory, which may be inflating price expectations.
Given the blend of aggressive growth, defensive sector positioning, and significant valuation compression, investors should treat the stock as a high‑risk growth play. The upside potential of roughly 9% is modest against a backdrop of high leverage, negative cash flow from operations, and a lack of dividend income. A cautious stance—monitoring for a breakout above resistance or a deterioration in the debt profile—is advisable before committing capital.
Given the blend of aggressive growth, defensive sector positioning, and significant valuation compression, investors should treat the stock as a high‑risk growth play. The upside potential of roughly 9% is modest against a backdrop of high leverage, negative cash flow from operations, and a lack of dividend income. A cautious stance—monitoring for a breakout above resistance or a deterioration in the debt profile—is advisable before committing capital.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with decreasing volume
- Technical bullish MACD but high short‑term volatility
- Valuation gap between market price and DCF fair value
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Robust 44% revenue growth trajectory
- Bullish MACD and favorable analyst consensus
- Defensive consumer sector positioning
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Elevated debt‑to‑equity ratio and negative earnings
- Absence of dividend and low ROE
- Potential for sector‑driven stability but valuation concerns
Key Metrics & Analysis
Financial Health
Revenue Growth44.40%
Profit Margin-5.59%
P/E Ratio45.1
ROE-23.98%
ROA-0.86%
Debt/Equity269.70
P/B Ratio-39.2
Op. Cash Flow$-8656000
Free Cash Flow$27.0M
Technical Analysis
TrendNeutral
RSI54.9
Support$6.81
Resistance$8.45
MA 20$7.58
MA 50$8.11
MA 200$5.61
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Fair Value$2.96
Target Price$8.88
Upside/Downside9.30%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.82
Volatility67.56%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.